Neonatal micropenis and cryptorchidism raise the suspicion of congenital hypogonadotropic hypogonadism (CHH), a rare genetic disorder caused by gonadotropin-releasing hormone deficiency. Low plasma testosterone levels and low gonadotropins during minipuberty provide a clinical diagnostic clue, yet these tests are seldomly performed in general practice. We report a male neonate with no family history of reproductive disorders who was born with micropenis and cryptorchidism. Hormonal testing at age 2.5 months showed low testosterone (0.3 nmol/L) and undetectable gonadotropins (luteinizing hormone and follicle-stimulating hormone both <0.5 U/L), suggestive of CHH. Genetic testing identified a de novo, heterozygous mutation in fibroblast growth factor receptor 1 (FGFR1 p.L630P). L630 resides on the ATP binding cleft of the FGFR1 tyrosine kinase domain, and L630P is predicted to cause a complete loss of receptor function. Cell-based assays confirmed that L630P abolishes FGF8 signaling activity. Identification of a loss-of-function de novo FGFR1 mutation in this patient confirms the diagnosis of CHH, allowing for a timely hormonal treatment to induce pubertal development. Therefore, genetic testing can complement clinical and hormonal assessment for a timely diagnosis of CHH in childhood.
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| Genetic analysis
After obtaining written informed consent for genetic studies, exome sequencing was performed in the proband and his parents using previously described methods 5 and data were filtered for mutations in known CHH genes. 1 A putative mutation is defined if a variant: (1) has a minor allele frequency of <1% in non-Finnish European controls from the Exome Aggregation Consortium (ExAC) database, and (2) is a nonsense, frameshift, or missense variant predicted to be damaging by SIFT (Sorting Tolerant From Intolerant) and/or PolyPhen-2. Identified mutations were further tested by Sanger sequencing. 6 Paternity was confirmed using all exome variants to calculate relatedness 7 using the relatedness2 function of VCF (variant call format) tools. 8 The clinical and genetic studies were approved by the ethics committee of the University of Lausanne.
| Functionality studies of FGFR1 L630P
The crystal structure of the tyrosine phosphorylated kinase domain of human FGFR1 complexed with non-hydrolysable ATP analog (PDB ID 3GQI) was used as template to predict the functional consequences of the FGFR1 L630P mutation, as previously reported. 6 HEK 293T cells were transfected with FGFR1 wide type (WT) and L630P constructs. Cell lysates were subjected to endoglycosidase digestion and then western blot analysis to determine the overall expression and maturation levels. 6 Cell surface abundance was measured by radiolabeled antibody binding assay using COS7
cells. 6 The activation of downstream signaling pathways by FGFR1
WT and L630P was interrogated using the osteocalcin-FGF response element reporter, which reports activity of the mitogen activated protein kinases (MAPK) pathway. Transient transfection and luciferase assays in L6 myoblasts stimulated by FGF8 were performed as previously described. 6 3 | RESULTS
| Genetic testing identified a de novo FGFR1 p.L630P mutation
The proband harbors a de novo heterozygous mutation (c.1889T>C, p.L630P) in FGFR1 (NM_023110) ( Figure 1A ). This mutation is not found in ExAC controls and is predicted to be deleterious by both SIFT and Polyphen2. No additional mutation in other known CHH genes was found.
| FGFR1 L630P mutant is loss-of-function in vitro
The L630 amino acid residue maps to the highly conserved tyrosine yielded a typical sigmoidal dose-response curve ( Figure 1F ). In contrast, the L630P mutant was completely silent, reflecting the defective kinase activity as predicted by structural modeling ( Figure 1F ).
| Confirmation of CHH diagnosis leads to optimal clinical management
The combined clinical, genetic, and functional investigations con- Genetic testing is of particular utility in cases of neonatal suspicion in order to strengthen the diagnostic of CHH as well as to provide genetic counseling to the family. Previous reports described genetic testing in familial cases using Sanger sequencing. of CHH patients; while a panel testing of 10 CHH genes costs 2900 CHF (including bioinformatic support), which will lead to a much higher diagnostic yield. In this study, we performed exome sequencing because the patient participated in a larger research project and exome sequencing provides a further advantage for novel gene discovery in case of no mutation in known CHH genes can be identified.
As emphasized in recent guidelines, one major challenge of genetic testing is the interpretation of the identified variant(s). 12 In this case, several lines of evidence support that the FGFR1 p.L630P mutation is pathogenic: (1) this mutation is absent in ExAC controls and has been previously identified in an unrelated female patient with Kallmann Syndrome (CHH and ansomia) 13 ; (2) the de novo nature of this mutation is consistent with the absence of family history; and 
